top of page

FDA Approves Talzenna Plus Xtandi in Hormone-Sensitive Prostate Cancer
10/26/26, 3:00 PM
The FDA approved Talzenna plus Xtandi for adults with HRR-mutated metastatic prostate cancer that has not been treated with, or is still responding to, androgen pathway drugs.

bottom of page
.png)